在预防ERCP后胰腺炎方面,直肠迪克洛菲纳克与印米他辛相比:系统性审查和元分析
Muhammad Arham1, Adnan Bhat2, Zahra Ali3
1Department of Medicine, Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan.
结肠直肠二二和印米他辛在预防ERCP后胰腺炎 (PEP) 中表现出类似的有效性和安全性. 临床医生可以根据PEP预防的成本和可用性进行选择.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 后内镜逆行性胆固醇胰腺炎 (PEP) 是一个显著的风险,影响高风险患者的高达40%.
- 推使用直肠非类固醇抗炎药物 (NSAIDs) 来预防PEP,但直接比较是有限的.
研究的目的:
- 系统地比较直肠迪克洛菲纳克与印米他辛在预防PEP方面的疗效和安全性.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 包括四项研究 (三项RCT,一项观察性) 直接比较直肠二二和印米他辛.
- 使用GRADE评估的风险比率和证据确定性.
主要成果:
- 在整体,轻度,中度或严重的PEP中,迪克洛芬雅克和印米他辛之间没有显著的差异.
- 这两种NSAID之间死亡率和并发症的比较率.
- 在所有结果中观察到的低异质性,表明可靠的发现.
结论:
- 结肠直肠二二和印米他辛在预防PEP方面表现出相当的疗效和安全性.
- 迪克洛芬雅克和印梅他辛之间的选择可以由成本和可用性等因素来指导.
更多相关视频
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
05:39Acupoint Needle-Embedding Combined with Ironing Therapy for Postoperative Pain After Anal Surgery
Published on: June 23, 2023
相关概念视频
Endoscopic Procedures V: ERCP
Patient...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Acute Pancreatitis II: Clinical Manifestations and Management
